RemeGen’s RC108 Receives FDA Go-Ahead for Phase I Clinical Study
China-based biopharma RemeGen Ltd (HKG: 9995) has announced receiving approval from the US FDA to...
Simcere Receives NMPA Clearance for SIM0348 Clinical Study
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...
Skynor Medical Raises RMB 100 Million in Financing Round for Market Expansion
Skynor Medical, a Shanghai-based manufacturer of nerve and peripheral blood vessel implantation and interventional devices,...
Sichuan Kelun Completes RMB 1.5 Billion Financing Round for Kelun-Biotech
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced the completion of a financing...
Everest Medicines’ Nefecon Receives Priority Review Recommendation from CDE
China-based Everest Medicines (HKG: 1952) has announced that the Center for Drug Evaluation (CDE) of...
BrightGene Receives NMPA Approval for BGM0504 Clinical Trial
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced that it has received clinical...
Anhui Anke Biotechnology Receives NMPA Approval for AK2017 Clinical Study
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced receiving approval from the...
AstraZeneca’s Nexium Approved by NMPA for Adolescent GERD Treatment
UK-based pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving market approval from the National Medical...
Sino Biopharmaceutical Secures Rights to Shionogi’s COVID-19 Therapy Ensitrelvir
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia Tai Tianqing...
Shenzhen Core Medical Raises ‘Hundreds of Millions’ in Series C Financing
Shenzhen-based heart failure mechanical circulatory support solutions provider, Shenzhen Core Medical Technology Co., Ltd, has...
Sinovac Reports H1 2022 Financials Amid COVID-19 Vaccine Demand Decline
China-based Sinovac Biotech Ltd (NASDAQ: SVA) has released its financial report for the first half...
Junshi Biosciences’ JT001 (VV116) Shows Non-Inferiority to Paxlovid in COVID-19 Trial
The results of a Phase III clinical study for China-based Junshi Biosciences’ (HKG: 1877, SHA:...
Hainan Shuangcheng Files Paragraph IV Patent Declaration for Paclitaxel, Albumin-Bound
China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has announced a Paragraph IV patent declaration...
Grand Pharma’s COVID-19 Therapy GS221 Shows Promising Safety Profile
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its clinical study for the...
Fosun Pharma Launches Online Registration for BioNTech COVID-19 Vaccine in Hong Kong
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced a new initiative...
Immunotech Biopharm’s CAR-T-19-D2 IND Filing Accepted by NMPA
China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...
Acotec Scientific Holdings Receives NMPA Approvals for YAN and P-Conic Balloon
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving market approvals from the National...
CanSino Biologics Updates Data from COVID-19 Vaccine Clinical Studies
China-based CanSino Biologics (HKG: 6185) has provided data updates from three clinical studies for its...
Fortune Care Raises Over RMB 100 Million in Series C+ Financing Round
China-based household healthcare and nursing brand Fortune Care reportedly raised over RMB 100 million (USD...
Guangzhou Mygene Raises ‘Hundreds of Millions’ in Series C Financing Led by Efund Capital
China-based molecular diagnostic product developer Guangzhou Mygene Medical Technology Co., Ltd reportedly raised “hundreds of...